The global treatment market for acute bacterial skin and skin structure infections (ABSSSI) is projected to increase at a compound annual growth rate of 9.6%, for an incremental revenue of $23.3 billion by 2032, according to a press release. Hospital-acquired ABSSSIs are forecasted as the highest-growing segment of all ABSSI, while hospital pharmacies accounted for the greatest market share in the forecast period. North America held the greatest revenue share, at 34.5%. Factors influencing the growth of the ABSSSI treatment market include higher rates of chronic diseases, technological advances in the diagnosis and treatment of ABSSSI, greater demand for antibacterial agents, an expanding elderly population, and greater awareness of these infections among the general population. Circumstances that may restrict such growth include higher rates of antimicrobial resistance and the use of generic drugs.
